Comparative Pharmacology
Head-to-head clinical analysis: MAVIK versus VASOTEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAVIK versus VASOTEC.
MAVIK vs VASOTEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Angiotensin-converting enzyme (ACE) inhibitor; inhibits ACE, preventing conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure and reduced cardiac workload.
Enalaprilat, the active metabolite of enalapril, competitively inhibits angiotensin-converting enzyme (ACE), preventing conversion of angiotensin I to angiotensin II. This reduces vasoconstriction, aldosterone secretion, and sodium reabsorption, leading to decreased blood pressure and afterload.
Oral, 1-4 mg once daily for hypertension; 2-4 mg once daily for heart failure.
2.5 to 10 mg orally twice daily; initial dose 5 mg once daily; titrate based on blood pressure response; maximum 40 mg/day.
None Documented
None Documented
Trandolaprilat: terminal half-life ~24 hours (range 15–35 hours) for once-daily dosing; effective half-life ~6–10 hours at steady state.
Terminal half-life of enalaprilat is 35-38 hours, with multiple-dose half-life ~11 hours due to prolonged terminal phase; clinical context: once-daily dosing achieves steady-state in 3-4 days.
Renal: trandolapril ~33% (as trandolaprilat and metabolites), trandolaprilat ~33% (as unchanged and metabolites); biliary/fecal: ~66% of total radioactivity.
Renal: 60-70% as enalaprilat; fecal: 20-30% as enalaprilat; biliary: minor (<10%).
Category C
Category C
ACE Inhibitor
ACE Inhibitor